CN Mobile Logo


Lung Cancer

Older Early-Stage NSCLC Patients Benefit From Adjuvant Chemotherapy

Early-stage non–small-cell lung cancer patients over 70 years old derive a similar benefit as younger patients from adjuvant chemotherapy following surgical resection. Image © pruit phatsrivong / Shutterstock.com.

Lung Cancer

The US Food and Drug Administration (FDA) today announced that it has granted accelerated approval for Merck’s anti-PD-1 agent pembrolizumab (Keytruda) for treating patients with refractory metastatic non-small cell lung cancer (NSCLC) tumors that express programmed cell death protein ligand 1 (PD-L1).

In this interview we discuss a new trial involving the antibody-drug conjugate IMMU-132 as well as the future of chemotherapy in the treatment of lung cancer.

Seventy-five percent of patients diagnosed with metastatic adenocarcinoma of the lung before age 40 have an actionable mutation, according to preliminary results from the Genomics of Young Lung Cancer Study.

Patients with stage IV squamous cell lung cancer positive for an EGFR gene copy number biomarker saw a survival benefit when adding cetuximab to chemotherapy.

The newly revised 8th edition of the tumor, node, and metastasis (TNM) classification of lung cancer will improve the precision of staging and provide physicians with new data with which to treat patients.

The incidence of NSCLC among self-reported never-smokers appears to be increasing, according to authors of two retrospective studies presented at the 2015 World Conference on Lung Cancer.

The investigational agent IMMU-32 is well-tolerated in patients with previously-treated metastatic lung cancer, and interim survival data are “encouraging.”


Subscribe to Lung Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.